Profile of bosutinib and its clinical potential in the treatment of chronic myeloid leukemia
Open Access
- 1 March 2013
- journal article
- review article
- Published by Taylor & Francis in OncoTargets and Therapy
- Vol. 6, 99-106
Abstract
Peer reviewed article authored by (Keller-von Amsberg G, Koschmieder S). Read article or submit your manuscript for publishing.Keywords
This publication has 51 references indexed in Scilit:
- Bosutinib Versus Imatinib in Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia: Results From the BELA TrialJournal of Clinical Oncology, 2012
- Novel aspects of therapy with the dual Src and Abl kinase inhibitor bosutinib in chronic myeloid leukemiaExpert Review of Anticancer Therapy, 2012
- Nilotinib vs imatinib in patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase: ENESTnd 3-year follow-upLeukemia, 2012
- Bosutinib is active in chronic phase chronic myeloid leukemia after imatinib and dasatinib and/or nilotinib therapy failureBlood, 2012
- Structural and Spectroscopic Analysis of the Kinase Inhibitor Bosutinib and an Isomer of Bosutinib Binding to the Abl Tyrosine Kinase DomainPLOS ONE, 2012
- Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML)Leukemia, 2012
- Chronic Myeloid Leukemia: Clinical Impact of BCR-ABL1 Mutations and Other Lesions Associated With Disease ProgressionSeminars in Oncology, 2012
- Assessment of BCR-ABL1 Transcript Levels at 3 Months Is the Only Requirement for Predicting Outcome for Patients With Chronic Myeloid Leukemia Treated With Tyrosine Kinase InhibitorsJournal of Clinical Oncology, 2012
- Safety and efficacy of bosutinib (SKI-606) in chronic phase Philadelphia chromosome–positive chronic myeloid leukemia patients with resistance or intolerance to imatinibBlood, 2011
- Kill one bird with two stones: potential efficacy of BCR-ABL and autophagy inhibition in CMLBlood, 2011